

An Insight into the Structure-Activity Relationship of Antimicrobial Peptide Brevinin

Md. Kamrul Hasan Arnab¹, Moynul Hasan¹, and Md. Monirul Islam^{2}*

¹Department of Pharmacy, Jagannath University, Dhaka, Bangladesh.

²Department of Pharmacy, Noakhali Science and Technology University, Noakhali, Bangladesh.

ABSTRACT

Numerous amphibian species, particularly those of the genus *Rana*, have been found to produce linear, amphiphilic, and cationic antimicrobial peptides (AMPs). Such AMPs are gaining more attention in pharmaceutical applications due to their principal method of action, which involves penetrating and rupturing the intended cell membranes with relatively low resistance. Brevinin is a large family of AMPs extensively studied during the last few decades, primarily consisting of two groups of peptides: Brevinin-1 and Brevinin-2. These peptides are cationic and establish secondary structures in the biological membrane environment. In this discussion, we explore the effects of structural parameters (net charge, hydrophobicity, amphiphilicity, helicity, peptide length, etc.) of Brevinin on their antimicrobial activity. As a general rule, an increased net charge tends to enhance antimicrobial activity. However, it is important to note that excessive net charges can also elevate hemolytic activity. The amino acid composition significantly influences hydrophobicity and helicity, which, in turn, impact the activity of the peptides. Moreover, these structural parameters are interconnected; modifying one parameter will affect others. Striking an optimal balance in these factors will provide a Brevinin analog with the highest antimicrobial activity and the lowest hemolytic activity.

Keywords: Antimicrobial peptides; Brevinin; Helicity; Hydrophobicity; Net charge; Hemolytic activity.

1. INTRODUCTION

The irrational use of antibiotics contributes to antimicrobial resistance in infectious pathogens, posing a severe global public health concern [1]. Increased antimicrobial resistance has resulted in the failure of traditional medicine to treat conditions effectively, heightened infection risks, prolonged hospital admissions, and, ultimately, an economic burden on nations [2, 3]. Therefore, it is vitally necessary to develop active antimicrobial compounds with lower resistance levels.

Antimicrobial peptides (AMPs) play a significant role in combating resistant microbes due to their rapid and broad-spectrum effectiveness against fungi, viruses, and

both Gram-positive and Gram-negative bacteria [4, 5]. In contrast to conventional antibiotics, AMPs bind to the bacterial membrane, causing disruption rather than targeting a specific site. The barrel-stave, carpet, or toroidal models are employed to describe the membrane disruption caused by AMPs [6-8], making it challenging for microorganisms to develop resistance against them [9].

AMPs are typically small, naturally occurring peptide molecules consisting of 10 to 50 amino acids. Most AMPs carry a net positive charge at physiological pH due to the presence of basic amino acids, facilitating electrostatic interactions with the membranes of negatively charged microorganisms [10]. An important structural feature of these peptides is amphiphilicity, characterized by the presence of hydrophobic residues on one side and hydrophilic residues on the other side of the molecule [11]. Amphiphilicity also aids in binding to the hydrophobic and hydrophilic regions of the target pathogen. In the presence

*Corresponding author: Monirul Islam

monirul.phrm@nstu.edu.bd

Received: 26/6/2023 Accepted: 10/9/2023.

DOI: <https://doi.org/10.35516/jjps.v16i4.1327>

of lipid membranes, many AMPs adopt a distinct secondary structure, such as α -helix or β -sheet, essential for antibacterial activity [12, 13].

AMPs are ubiquitous in almost every living organism, serving as a component of their innate immune system. Extracted from the skin of amphibians, these AMPs have demonstrated superior efficacy against microorganisms, offering a potential solution to current antimicrobial resistance problems [14].

Amphibian AMPs are categorized into peptide families, including brevinins, cathelicidin, temporins, esculentin, ranatuerin, etc., based on shared structural properties and their ability to combat pathogens [15]. Brevinin (Figure 1) is a crucial amphibian AMP family isolated from the Ranidae, exhibiting high biological activities and distinctive structural properties [16]. Originally identified in *Rana brevipoda porsa* [17], hundreds of Brevinin peptides have been discovered and their data deposited in the database [18]. These peptides exhibit various bioactivities, encompassing antimicrobial, anticancer, hypoglycemic,

anti-inflammatory, and more [19].

Researchers have designed numerous Brevinin analogs, aligning with common AMP features and the predicted secondary structure of peptides, to explore the structure-activity relationship and enhance their antimicrobial activity. For instance, Lin et al. extracted Brevinin-2GUb from the skin secretion of *Hylarana guentheri*, producing analogs to investigate its cationic activity [20]. The augmentation of cationic charges significantly enhances the compound's bioactivity while mitigating its toxicity effects. AMPs exhibit various structural parameters (amphiphilicity, net charge, charge density, length, hydrophobicity, hydrophobic moment, and helicity) influencing antimicrobial activity. Hence, this study delves into the structural features of Brevinin analogs and the impact of structural changes on their antimicrobial activity. Understanding the structural activity relationship of Brevinins is crucial for identifying the most effective peptide to serve as a template for developing new antimicrobial agents with medicinal properties.




Figure 1. Chemical structure of Brevinin-1

2. Importance of SAR study of Brevinin

A structure-activity relationship (SAR) study is crucial for understanding the correlation between structural parameters and the antimicrobial activity of peptides. Researchers can create synthetic analogs of parent peptides to enhance antimicrobial efficacy. For example, synthetic hybrid peptides derived from natural indolicidin

and ranalexin exhibit greater antibacterial activity compared to their parent analogs against *Streptococcus pneumoniae* [21]. Larger antimicrobial peptides may demonstrate increased hemolytic tendencies, whereas shorter peptides with higher cationic content tend to reduce hemolytic activity [22].

An in-depth exploration of peptide structure is essential

for the rational design of α -helical AMPs with heightened antimicrobial activity and specificity [23]. Examining the SAR of AMPs is also vital for comprehending the diverse mechanisms responsible for the antimicrobial activities of peptides [24]. It is imperative for researchers to expand SAR studies to unearth novel peptide analogs with

enhanced antimicrobial activity. Brevinin, a substantial group of AMPs, exhibits a broad-spectrum activity against bacteria, viruses, fungi, and other parasites (Table 1). Understanding the structure-activity relationship of Brevinin is pivotal for discovering more bioactive analogs, contributing to advancements in medical science.

Table 1. Some notable Brevinin family AMPs with their sequences, sources, and major bioactivities

| Name | Length | Amino Acid Sequence* | Bioactivities | Source | References |
|----------------|--------|--------------------------|---|-------------------------------|------------|
| Brevinin-1 | 24 | FLPVLGIAAKVVPALFCKITKCC | Antibacterial, high hemolytic activity | <i>Rana brevipoda porsa</i> | [17] |
| Brevinin-1AVa | 17 | FLPLLAASFACTVTKCC | Antibacterial | <i>Rana arvalis</i> | [25] |
| Brevinin-1Ba | 24 | FLPFIAGMAAKFLPKIFCAISKCC | Antibacterial | <i>Lithobates berlandieri</i> | [26] |
| Brevinin-1BYa | 24 | FLPILASLAAKFGPKLFLVTKCC | Antibacterial, antifungal and hemolytic activity | <i>Rana boylei</i> | [27] |
| Brevinin-1CDYa | 20 | LLSLALAALPKLFLIFKCC | Antibacterial and weak hemolytic activity | <i>Rana chensinensis</i> | [28] |
| Brevinin-1CG1 | 24 | FLSTALKVAANVPTLFCITKCC | Antibacterial, antifungal and low hemolytic activity | <i>Amolops chunganensis</i> | [29] |
| Brevinin-1CSa | 24 | FLPILAGLAAKIVPKLFLATKCC | Antibacterial and strong hemolytic activity | <i>Rana cascadae</i> | [30] |
| Brevinin-1DYb | 20 | FLSLALAALPKLFLIFKCC | Antibacterial, antifungal, anticancer, candidacidal and strong hemolytic activity | <i>Rana dybowskii</i> | [31] |
| Brevinin-1E | 24 | FLPLLAGLAANFLPKIFCKITRCC | Antibacterial | <i>Pelophylax saharicus</i> | [32] |
| Brevinin-1HN1 | 24 | FLPLIASLAANFVPKIFCKITKCC | Antibacterial, antifungal, candidacidal and low hemolytic activity | <i>Odorana hainanensis</i> | [33] |
| Brevinin-1HSa | 24 | FLPAVLRVAAKIVPTVFCAISKCC | Antibacterial activity | <i>Odorana hosii</i> | [34] |
| Brevinin-1ITa | 20 | IVPFLGGMVPKLVCLITKCC | Antibacterial, cytotoxic and hemolytic activity | <i>Rana italica</i> | [35] |
| Brevinin-1OKa | 22 | FFGSMIGALAKGLPSLISLIKK | Antibacterial | <i>Rana okinavana</i> | [36] |
| Brevinin-1OKc | 22 | FFGSIIIGALAKGLPSLISLIKK | Antibacterial | <i>Rana okinavana</i> | [36] |
| Brevinin-1Pa | 24 | FLPIIAGVAAKVFPKIFCAISKCC | Antibacterial, antifungal and candidacidal activity | <i>Rana pipiens</i> | [26] |
| Brevinin-1PLb | 24 | FLPLIAGLAANFLPKIFCAITKCC | Antibacterial, antifungal and candidacidal activity | <i>Lithobates palustris</i> | [37] |
| Brevinin-1Ra | 24 | VIPFVASVAEEMMQHVYCAASRRC | Antibacterial | <i>Pelophylax ridibundus</i> | [38] |

| Name | Length | Amino Acid Sequence* | Bioactivities | Source | References |
|---------------|--------|---------------------------------------|---|-----------------------------------|------------|
| Brevinin-1Sa | 24 | FLPAIVGAAGQFLPKIFCAISKKC | Antibacterial and antifungal activity | <i>Rana sphenocephala</i> | [39] |
| Brevinin-1SE | 23 | FLPLVRGAAKLIPSVVCAISKRC | Antibacterial activity | <i>Rana sevosia</i> | [40] |
| Brevinin-1SN1 | 24 | FLPAVLKVA AHILPTAICAI SRRC | Antibacterial and hemolytic activity | <i>Hylarana spinulosa</i> | [41] |
| Brevinin-1SPa | 24 | FFPIIAGMAAKLIPSLFCKITKCC | Antibacterial, antifungal, candidacidal and hemolytic activity | <i>Lithobates septentrionalis</i> | [42] |
| Brevinin-1T | 20 | VNPIILGVLPKFVCLITKCC | Antibacterial, high hemolytic activity | <i>Rana temporaria</i> | [43] |
| Brevinin-2 | 33 | GLLDSLKGFAATAGKGVLSLLSTASCKLAKTC | Antibacterial, high hemolytic activity | <i>Rana brevipoda porsa</i> | [17] |
| Brevinin-2DYE | 37 | GLFSVVTGVLKAVGKNVAKNVGGSLLEQLKCKISGGC | Antibacterial | <i>Rana dybowskii</i> | [31] |
| Brevinin-2GHb | 30 | GVITDALKGAAKTVAEELLRKAHCKLTNSC | Antibacterial | <i>Rana guentheri</i> | [44] |
| Brevinin-2GHc | 31 | SIWEGIKNAGKGFVLSILDKVRCKVAGGCN P | Antibacterial | <i>Hylarana guentheri</i> | [44] |
| Brevinin-2GRa | 33 | GLLDTFKNLALNAAKSAGVSVLNSLSCKLSKTC | Antibacterial, antifungal, candidacidal and hemolytic activity | <i>Odorrana grahami</i> | [45] |
| Brevinin-2ISa | 33 | SLLDTFKNLAVNAAKSAGVSVLNSLSCKISR TC | Antibacterial, Antifungal and candidacidal activity | <i>Odorrana ishikawae</i> | [46] |
| Brevinin-2JD | 33 | GLLDTFKNLALNAAKSAGVSVLNSLSCKLSKTC | Antibacterial, antifungal, candidacidal and weak hemolytic activity | <i>Odorrana jingdongensis</i> | [47] |
| Brevinin-2LT | 33 | GLMSVLKKGAKHVAKNVAASLMDSLKCKITGGC | Antibacterial | <i>Rana latastei</i> | [48] |
| Brevinin-2R | 25 | KLKNFAKGVAQSLLNKASCKLSGQC | Antibacterial, antifungal, anticancer, candidacidal activity | <i>Pelophylax ridibundus</i> | [49] |
| Brevinin-2Ra | 29 | GILDSLKNFAKDAAGILLKKASCKLSGQC | Antibacterial | <i>Pelophylax ridibundus</i> | [50] |
| Brevinin-2Ta | 33 | GILDTLKNLAKTAGKILKSLVNTASCKLSGQC | Antibacterial, antifungal, candidacidal, anti-inflammatory and wound-healing activity | <i>Pelophylax kl. esculentus</i> | [51] |
| Brevinin-Eu | 24 | VIPFVASVA AEMMQHIFCAASRKC | Antibacterial, very low hemolytic activity | <i>Euphlyctis cyanophlyctis</i> | [52] |
| Brevinins-ALa | 24 | FLPMLAGLAANFLPKLFCKITKCC | Antibacterial, antifungal, and strong hemolytic activity | <i>Amolops loloensis</i> | [53] |

*Refer to **table S1** in the appendix

3. Structural features of Brevinin

The Brevinin family is divided into two subfamilies: Brevinin-1 and Brevinin-2. Brevinin-1 (FLPVLGIAAKVVPALFCKITKCC) comprises

approximately 24 residues, while Brevinin-2 (GLLDSLKGFAATAGKGVLSLLSTASCKLAKTC) has a length of approximately 33 residues. Brevinin-1 exists in two forms: cyclic and acyclic Brevinin-1 [36]. Acyclic

Brevinin-1 lacks Cys residues but has an amidated C-terminus, while cyclic Brevinin-1 features a disulfide bond at its C-terminus. Although the primary structure of Brevinins may vary among species, they typically contain a highly conserved portion in the 'Rana box' sequence. The Rana box is usually situated at the C-terminus, and its structure is [Cys18-(Xaa)4-Lys-Cys24] for Brevinin-1 [54]. While the length and amino acid composition of the peptides may vary, they all carry a net positive charge at neutral pH. Bacterial cell membranes, lacking neutral and zwitterionic lipids compared to mammalian cell membranes, make it easier for Brevinins

to selectively attach to the anionic phospholipids of bacterial cell membranes [55].

Brevinins typically exist as randomly arranged coils in an aqueous solution but adopt an amphipathic α -helical shape in environments that mimic hydrophobic membranes, such as 50% trifluoroethanol (TFA) [56]. The peptide structure and the side chains of Brevinin-1 in a 33% trifluoroethanol solution are depicted in Figure 2. The α -helical structure is believed to disturb the phospholipid bilayer of the targeted membranes under such circumstances.




Figure 2. Structure of Brevinin-1BYa. (A) The solution NMR structure of Brevinin-1BYa in 33% trifluoroethanol (PDB ID: 6G4I) visualized in PyMOL (version 2.4.1.), (B) Helical wheel representation of Brevinin-1BYa obtained from HeliQuest server (<https://www.heliquet.ipmc.cnrs.fr/>). The positively charged, negatively charged, hydrophobic, and hydrophilic amino acids are each represented by a different color: blue, red, yellow, and purple, respectively. The letters 'N' and 'C' stand for the N-terminal and C-terminal, respectively.

3.1. Net charge

The peptides belonging to the Brevinin family are cationic. Typically, the positively charged residues (arginine, lysine), combined with negatively charged residues (aspartate, glutamate) in the peptide sequence, are totaled to determine the net charge of a peptide. The positive charge of the peptide molecule plays a crucial role in binding to the negatively charged surface of microorganisms [57]. Previous studies suggest that

cationic peptides need a net charge of at least +2 to exhibit antibacterial effects effectively [58]. In general, higher net charge enhances the antibacterial action of peptides. For instance, Brevinin-2PTb (charge +5) demonstrates greater antimicrobial activity than Brevinin-2PTc (charge +4) and Brevinin-2HSa (charge +3) against *E. coli* 25726 [36]. However, it's essential to note that the impact of net charge is not always linear with activity. Another critical consideration is that an increased net charge of the peptide

also escalates hemolysis of human red blood corpuscles. Figure 3 illustrates the effects of net charge on the activity

of various peptides [59, 60, 41].




Figure 3. Relationship between charge and antimicrobial & hemolytic activity of Brevinin-2 related peptides (A) and Brevinin-1 peptides (B). The antimicrobial activity was measured in minimal inhibitory concentration (MIC) against *Staphylococcus aureus* 25923. The hemolysis of 50% human red blood cell concentration was considered as HC₅₀. ★ A marked point indicates a value greater than that point (>200μM).

Figure 3A illustrates that a peptide with a net charge of +4 exhibits the most potent antimicrobial activity, while one with a net charge of +2 shows hemolytic activity. Additional research by Islam et al. emphasizes that the optimal charge selection is crucial in peptide design to achieve maximum antimicrobial activity with minimal hemolysis [61]. In this context, we also observe that peptides with net charges of +3 and +5 display superior antimicrobial action with considerably low hemolytic activity.

Conversely, Figure 3B demonstrates that a peptide with a net charge of +5 has the best antimicrobial activity with the lowest hemolytic activity.

3.2. Hydrophobicity

The hydrophobicity of a peptide is measured by the solubility of its amino acids in water. The composition of a peptide determines its hydrophobicity, with a higher proportion of hydrophobic residues making the peptide

more hydrophobic and vice versa.

The hydrophobicity of an AMP is a critical factor for its insertion into the pathogen's membrane. Trp, a hydrophobic amino acid, enhances its ability to bind to lipids, influencing the interfacial region of lipid bilayers [62]. A hydrophobicity threshold is presumed to play a role in selective bacterial membrane insertion and subsequent cell death. However, increased peptide hydrophobicity is associated with higher hemolytic activity [63]. In a previous investigation, Brevinin-2PRc and Brevinin-2PRd showed lower toxicity against red blood cells because their hydrophobicity decreased when Phe was replaced with Leu [64]. Another study demonstrated a linear relationship between hydrophobicity and hemolytic activity [65]. Thus, scrutinizing peptide hydrophobicity is crucial to avoid hemolysis. In Figure 3, we depict the relationship between the hydrophobicity of several Brevinin peptides and their

antimicrobial and hemolytic activity [66, 29]. The peptides share similar net charges and lengths, and their hydrophobicity values were calculated using HeliQuest.

In Figure 4A, it is shown that peptides with lower hydrophobicity values exhibit lesser antimicrobial activity,

with the optimal action observed at 0.75; beyond this point, increasing hydrophobicity leads to a reduction in activity. The diminished activity of highly hydrophobic peptides is attributed to their self-aggregation, preventing them from passing through the microbial cell wall [63].




Figure 4. Relationship among hydrophobicity and antimicrobial activity (A) and hemolysis (B) of Brevinin peptides. The antimicrobial activity was measured in minimal inhibitory concentration (MIC) against *Escherichia coli* 25922. The *hemolysis of 50% human red blood cell concentration was considered as HC₅₀. Marked points indicate values greater than that point (>100µM).

Hemolytic activity demonstrates a direct proportionality to the hydrophobicity value of Brevinin peptides (Figure 4B). Given these two phenomena, it is advisable to design peptides with hydrophobicity that promotes antimicrobial activity while concurrently minimizing hemolytic activity.

3.3. Peptide length

The length and amino acid composition of Brevinins vary, but they all feature a distinctive "Rana Box" at the C-terminus, where positively charged residues cluster. Kumari and Nagaraj demonstrated that the disulfide bridge and the cationic cluster at the C-terminus of Brevinin 1E have no impact on antimicrobial activity but do affect hemolytic activity. Peptides lacking a disulfide bridge at the 'Rana Box' exhibit lower hemolytic activity due to a loss of rigidity [67]. Conversely, the activity of Brevinin-1GHa was diminished

by removing the Rana Box from the C-terminus [68]. This reduction in activity may be attributed to a decrease in helicity. The N-terminal end of Brevinin-2GUb contains active fragments from the first to the nineteenth amino acids. However, the amino acid composition should offer sufficient hydrophobicity and net charge for interaction with the microbial membrane [20]. Despite being a 12-amino-acid-containing peptide, Brevinin-1OSf exhibits superior antimicrobial and lower hemolytic activity compared to Brevinin-1OS (24 amino acids) [69]. A C-terminus truncated peptide, Brevinin-2GK (1-25), demonstrated higher antibacterial activity than the parent Brevinin-2GK (33 residues), despite having less hemolytic activity. This suggests that the N-terminal helical segment of Brevinin-2GK is the primary cause of membrane rupturing [70].

It is evident that maintaining a balance between α -

helicity, positive charge, and hydrophobicity, rather than peptide length, is crucial for effective antibacterial activity.

3.4. Amphiphilicity

The amphiphilic nature of a peptide is essential for membrane activity [11]. This characteristic enables the interaction with lipid heads on the membrane and deep insertion into the membrane by segregating hydrophobic residues to one side of the helix.

Analog studies of Brevinin-1OS demonstrated a direct proportionality between amphiphilicity and the

antimicrobial and hemolytic activity of peptides [69]. Figure 5 illustrates the linear relationship between the amphiphilicity index and the activity of four Brevinin-1 analogs (OSc, OSd, OSe, and OSf).

Among these peptides, the one with the lowest amphiphilicity exhibits the lowest activity (high MIC and HC₅₀ values). Activity against microbes and red blood cells increases with the rise in amphiphilicity. Therefore, selecting a peptide with high antimicrobial activity and considerably low hemolytic activity is of utmost importance.




Figure 5. Relationship between amphiphilicity index and activity of four Brevinin-1 analogs. The amphiphilicity index is obtained from the Database of Antimicrobial Activity and Structure of Peptides (<https://dbaasp.org/home>). The MIC value was measured against *Staphylococcus aureus* (NCTC 10788), and HC₅₀ was considered as the concentration required for the hemolysis of 50% of horse red blood cells. Marked points indicate values greater than that point (>512μM for HC₅₀).

3.5. Helicity

Helicity refers to the ability of an antimicrobial peptide to adopt a helical structure in a specific environment, such as negatively charged phospholipids in the bacterial cell membrane. Increased helicity enhances antimicrobial activity, selectivity, and stabilizes the α -helical structure.

The combination of α -helicity and hydrophobicity is heightened by a cationic charge, which, in turn, increases hemolytic activity compared to antimicrobial activity [71].

While the structural properties of peptide α -helices may be crucial for bacterial cell death, their content may not directly correlate with antibacterial efficacy [72]. For

instance, OSd, due to the formation of a greater amount of α -helical composition than OSc, exhibits significantly increased antibacterial activity. Despite a more pronounced α -helical structure, OSd is less effective in inhibiting bacterial growth compared to both OSe and OSf, which have lower helicity [69].

Analog studies of Brevinin-2GUB revealed reduced ability to generate a secondary structure (α -helix) in the analogs, resulting in lower activity on both the microbial surface and red blood cells [68]. A similar outcome was observed for BICTcu1, where the peptide's binding affinity to the bacterial membrane and hemolytic activity were relatively low due to its diminished capacity to adopt an α -helical structure [73].





4. CONCLUSION












Antimicrobial peptides (AMPs) represent a promising alternative to traditional antibiotic molecules due to their






remarkable activity against pathogenic species. Amphibian skin serves as an excellent source of animal AMPs, with Brevinin being a well-studied peptide over the past few decades. The activity of Brevinins can be modulated by manipulating various structural features. The net charge exhibits a direct relationship with activity, while hydrophobicity and α -helicity are predominantly associated with hemolytic activity. However, designing an active peptide requires consideration of multiple parameters. Positive charge, hydrophobicity, α -helicity, and amphipathicity interact intricately to delineate the cytolytic actions of Brevinins against both bacteria and mammalian cells. This study contributes to the design of novel, functional antimicrobial molecules with potential therapeutic applications.

Conflict of interest statement: The authors declared no conflict of interest.

Table S1: Amino acid coding system.

| Amino acid name | Abbreviation | Single letter abbreviation | Structure |
|-----------------|--------------|----------------------------|---|
| Alanine | Ala | A |  |
| Arginine | Arg | R |  |
| Asparagine | Asn | N |  |
| Aspartic acid | Asp | D |  |

| Amino acid name | Abbreviation | Single letter abbreviation | Structure |
|-----------------|--------------|----------------------------|---|
| Cysteine | Cys | C |  |
| Glutamic acid | Glu | E |  |
| Glutamine | Gln | Q |  |
| Glycine | Gly | G |  |
| Histidine | His | H |  |
| Isoleucine | Ile | I |  |
| Leucine | Leu | L |  |
| Lysine | Lys | K |  |
| Methionine | Met | M |  |
| Phenylalanine | Phe | F |  |
| Proline | Pro | P |  |

| Amino acid name | Abbreviation | Single letter abbreviation | Structure |
|-----------------|--------------|----------------------------|---|
| Serine | Ser | S |  |
| Threonine | The | T |  |
| Tryptophan | Trp | W |  |
| Tyrosine | Tyr | Y |  |
| Valine | Val | V |  |

REFERENCES

- Hejaz HA. Knowledge and Attitudes towards Antibiotic Usage. *Jordan J Pharm Sci.* 2023; 16(2): 447.
- Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization. 2014.
- Taha AA. Spectrum and Antibiotic Resistance in the Community and Hospital-Acquired Urinary Tract Infected Adults. *Jordan J Pharm Sci.* 2023 ;16(2): 455.
- Neshani A, Sedighian H, Mirhosseini SA. et al. Antimicrobial peptides as a promising treatment option against *Acinetobacter baumannii* infections. *Microb Pathog.* 2020; 146(104238): 104238.
- Zhao H, Zhou J, Zhang K. et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. *Sci Rep.* 2016; 6(1): 1-3.
- Sansom MS. The biophysics of peptide models of ion channels. *Prog Biophys Mol Biol.* 1991; 55(3): 139–235.
- Matsuzaki K, Murase O, Fujii N. et al. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. *Biochemistry.* 1996; 35(35): 11361–11368.
- Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by α -helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochim Biophys Acta Biomembr.* 1999; 1462(1–2): 55–70.
- Aoki W, Ueda M. Characterization of antimicrobial peptides toward the development of novel antibiotics. *Pharmaceuticals (Basel).* 2013; 6(8): 1055–1081.
- Hancock RE, Diamond G. The role of cationic antimicrobial peptides in innate host defences. *Trends Microbiol.* 2000; 8(9): 402–410.
- Tossi A, Sandri L, Giangaspero A. Amphipathic, α -helical antimicrobial peptides. *Biopolymers.* 2000; 55(1): 4–30.
- Takahashi D, Shukla SK, Prakash O. et al. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. *Biochimie.* 2010; 92(9): 1236–1241.
- Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends Biotechnol.* 2011; 29(9): 464–472.

14. Lee J-K, Luchian T, Park Y. New antimicrobial peptide kills drug-resistant pathogens without detectable resistance. *Oncotarget*. 2018; 9(21): 15616–15634.
15. Conlon JM. Structural diversity and species distribution of host-defense peptides in frog skin secretions. *Cell Mol Life Sci*. 2011; 68(13): 2303–2315.
16. Conlon JM, Kolodziejek J, Nowotny N. Antimicrobial peptides from ranid frogs: taxonomic and phylogenetic markers and a potential source of new therapeutic agents. *Biochim Biophys Acta Proteins Proteom*. 2004; 1696(1): 1–14.
17. Morikawa N, Hagiwara K, Nakajima T. Brevinin-1 and -2, unique antimicrobial peptides from the skin of the frog, *Rana brevipoda porsa*. *Biochem Biophys Res Commun*. 1992; 189(1): 184–190.
18. Novković M, Simunić J, Bojović V. et al. DADP: the database of anuran defense peptides. *Bioinformatics*. 2012; 28(10): 1406–1407.
19. Savelyeva A, Ghavami S, Davoodpour P. et al. An overview of Brevinin superfamily: structure, function and clinical perspectives. *Adv Exp Med Biol*. 2014; 818: 197–212.
20. Lin Y, Liu S, Xi X. et al. Study on the structure-activity relationship of an antimicrobial peptide, Brevinin-2GUb, from the skin secretion of *Hylarana guentheri*. *Antibiotics (Basel)*. 2021; 10(8): 895.
21. Jindal HM, Le CF, Mohd Yusof MY. et al. Antimicrobial activity of novel synthetic peptides derived from indolicidin and ranalexin against *Streptococcus pneumoniae*. *PLoS One*. 2015; 10(6): 0128532.
22. Albada HB, Prochnow P, Bobersky S. et al. Short antibacterial peptides with significantly reduced hemolytic activity can be identified by a systematic L-to-D exchange scan of their amino acid residues. *ACS Comb Sci*. 2013; 15(11): 585–592.
23. Chen Y, Mant CT, Farmer SW. et al. Rational design of α -helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. *J Biol Chem*. 2005; 280(13): 12316–12329.
24. Kumar P, Kizhakkedathu J, Straus S. Antimicrobial peptides: Diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules*. 2018; 8(1): 4.
25. Samgina TY, Artemenko KA, Gorshkov VA. et al. Mass spectrometric study of peptides secreted by the skin glands of the brown frog *Rana arvalis* from the Moscow region. *Rapid Commun Mass Spectrom*. 2009; 23(9): 1241–1248.
26. Goraya J, Wang Y, Li Z. et al. Peptides with antimicrobial activity from four different families isolated from the skins of the North American frogs *Rana luteiventris*, *Rana berlandieri* and *Rana pipiens*: Antimicrobial peptides from Ranid frogs. *Eur J Biochem*. 2000; 267(3): 894–900.
27. Conlon JM, Sonnevend A, Patel M. et al. Isolation of peptides of the brevinnin-1 family with potent candidacidal activity from the skin secretions of the frog *Rana boylei*. *J Pept Res*. 2003; 62(5): 207–213.
28. Jin LL, Song SS, Li Q. et al. Identification and characterisation of a novel antimicrobial polypeptide from the skin secretion of a Chinese frog (*Rana chensinensis*). *Int J Antimicrob Agents*. 2009; 33(6): 538–542.
29. Yang X, Xia J, Yu Z. et al. Characterization of diverse antimicrobial peptides in skin secretions of Chungan torrent frog *Amolops chunganensis*. *Peptides*. 2012; 38(1): 41–53.
30. Conlon JM, Al-Dhaheri A, Al-Mutawa E. et al. Peptide defenses of the Cascades frog *Rana cascadae*: implications for the evolutionary history of frogs of the Amerana species group. *Peptides*. 2007; 28(6): 1268–1274.
31. Conlon JM, Kolodziejek J, Nowotny N. et al. Cytolytic peptides belonging to the brevinnin-1 and brevinnin-2 families isolated from the skin of the Japanese brown frog, *Rana dybowskii*. *Toxicon*. 2007; 50(6): 746–756.
32. Marenah L, Flatt PR, Orr DF. et al. Skin secretions of *Rana saharica* frogs reveal antimicrobial peptides esculentins-1 and -1B and brevinnins-1E and -2EC with novel insulin releasing activity. *J Endocrinol*. 2006; 188(1): 1–9.
33. Wang H, Yu Z, Hu Y. et al. Novel antimicrobial peptides isolated from the skin secretions of Hainan odorous frog, *Odorana hainanensis*. *Peptides*. 2012; 35(2): 285–290.
34. Conlon JM, Kolodziejek J, Nowotny N. et al. Characterization of antimicrobial peptides from the skin secretions of the Malaysian frogs, *Odorana hosii* and *Hylarana picturata* (Anura: Ranidae). *Toxicon*. 2008; 52(3): 465–473.
35. Conlon JM, Musale V, Attoub S. et al. Cytotoxic peptides with insulin-releasing activities from skin secretions of the Italian stream frog *Rana italica* (Ranidae). *J Pept Sci*. 2017; 23(10): 769–776.
36. Conlon JM, Sonnevend A, Jouenne T. et al. A family of acyclic brevinnin-1 peptides from the skin of the Ryukyu brown frog *Rana okinavana*. *Peptides*. 2005; 26(2): 185–190.

37. Basir YJ, Knoop FC, Dulka J. et al. Multiple antimicrobial peptides and peptides related to bradykinin and neuromedin N isolated from skin secretions of the pickerel frog, *Rana palustris*. *Biochim Biophys Acta*. 2000; 1543(1): 95–105.
38. Samgina TY, Artemenko KA, Bergquist J. et al. Differentiation of frogs from two populations belonging to the *Pelophylax esculentus* complex by LC-MS/MS comparison of their skin peptidomes. *Anal Bioanal Chem*. 2017; 409(7): 1951–1961.
39. Conlon TJ, Halverson T, Dulka J. et al. Peptides with antimicrobial activity of the brevinin-1 family isolated from skin secretions of the southern leopard frog, *Rana sphenoccephala*. *J Pept Res*. 1999; 54(6): 522–527.
40. Graham C, Richter SC, McClean S. et al. Histamine-releasing and antimicrobial peptides from the skin secretions of the dusky gopher frog, *Rana sevosia*. *Peptides*. 2006; 27(6): 1313–1319.
41. Yang X, Hu Y, Xu S. et al. Identification of multiple antimicrobial peptides from the skin of fine-spined frog, *Hylarana spinulosa* (Ranidae). *Biochimie*. 2013; 95(12): 2429–2436.
42. Bevier CR, Sonnevend A, Kolodziejek J. et al. Purification and characterization of antimicrobial peptides from the skin secretions of the mink frog (*Rana septentrionalis*). *Comp Biochem Physiol C Toxicol Pharmacol*. 2004; 139(1–3): 31–38.
43. Simmaco M, Mignogna G, Barra D. Antimicrobial peptides from amphibian skin: what do they tell us? *Biopolymers*. 1998; 47(6): 435–450.
44. Zhou J, McClean S, Thompson A. et al. Purification and characterization of novel antimicrobial peptides from the skin secretion of *Hylarana guentheri*. *Peptides*. 2006; 27(12): 3077–3084.
45. Conlon JM, Al-Ghaferi N, Abraham B. et al. Antimicrobial peptides from diverse families isolated from the skin of the Asian frog, *Rana grahami*. *Peptides*. 2006; 27(9): 2111–2117.
46. Iwakoshi-Ukena E, Ukena K, Okimoto A. et al. Identification and characterization of antimicrobial peptides from the skin of the endangered frog *Odorrana ishikawae*. *Peptides*. 2011; 32(4): 670–676.
47. Liu J, Jiang J, Wu Z. et al. Antimicrobial peptides from the skin of the Asian frog, *Odorrana jingdongensis*: *de novo* sequencing and analysis of tandem mass spectrometry data. *J Proteomics*. 2012; 75(18): 5807–5821.
48. Samgina TY, Tolpina MD, Trebse P. et al. LTQ Orbitrap Velos in routine *de novo* sequencing of non-tryptic skin peptides from the frog *Rana latastei* with traditional and reliable manual spectra interpretation. *Rapid Commun Mass Spectrom*. 2016; 30(2): 265–276.
49. Ghavami S, Asoodeh A, Klonisch T. et al. Brevinin-2R1 semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. *J Cell Mol Med*. 2008; 12(3): 1005–1022.
50. Samgina TY, Artemenko KA, Gorshkov VA. et al. *De novo* sequencing of peptides secreted by the skin glands of the Caucasian Green Frog *Rana ridibunda*. *Rapid Commun Mass Spectrom*. 2008; 22(22): 3517–3525.
51. Lamb R, Bonuccelli G, Ozsvári B. et al. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. *Oncotarget*. 2015; 6(31): 30453–30471.
52. Asoodeh A, Sepahi S, Ghorani-Azam A. Purification and Modeling Amphipathic Alpha Helical Antimicrobial Peptides from Skin Secretions of *Euphylyctis cyanophlyctis*. *Chem Biol Drug Des*. 2014; 83(4): 411–417.
53. Lu Y, Li J, Yu H. et al. Two families of antimicrobial peptides with multiple functions from skin of rufous-spotted torrent frog, *Amolops loloensis*. *Peptides*. 2006; 27(12): 3085–3091.
54. Clark DP, Durell S, Maloy WL. et al. A novel antimicrobial peptide from bullfrog (*Rana catesbeiana*) skin, structurally related to the bacterial antibiotic, polymyxin. *J Biol Chem*. 1994; 269(14): 10849–10855.
55. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. *Pharmacol Rev*. 2003; 55(1): 27–55.
56. Kwon M-Y, Hong S-Y, Lee K-H. Structure-activity analysis of brevinin 1E amide, an antimicrobial peptide from *Rana esculenta*. *Biochim Biophys Acta*. 1998; 1387(1–2): 239–248.
57. Lee T-H, N. Hall K, Aguilar M-I. Antimicrobial peptide structure and mechanism of action: A focus on the role of membrane structure. *Curr Top Med Chem*. 2015; 16(1): 25–39.
58. Jiang Z, Vasil AI, Hale JD. et al. Effects of net charge and the number of positively charged residues on the biological activity of amphipathic α -helical cationic antimicrobial peptides. *Peptide Science*. 2008; 90(3): 369–383.
59. Conlon JM, Ahmed E, Condamine E. Antimicrobial properties of brevinin-2-related peptide and its analogs: efficacy against multidrug-resistant *Acinetobacter baumannii*. *Chem Biol Drug Des*. 2009; 74(5): 488–493.

60. Guo C, Hu Y, Li J. et al. Identification of multiple peptides with antioxidant and antimicrobial activities from skin and its secretions of *Hylarana taipehensis*, *Amolops lifanensis*, and *Amolops granulosis*. *Biochimie*. 2014; 105: 192–201.
61. Islam MM, Asif F, Zaman SU. et al. Effect of charge on the antimicrobial activity of alpha-helical amphibian antimicrobial peptide. *Curr Res Microb Sci*. 2023. 100182.
62. Situ AJ, Kang S-M, Frey BB. et al. Membrane anchoring of α -helical proteins: Role of tryptophan. *J Phys Chem B*. 2018; 122(3): 1185–1194.
63. Chen Y, Guarnieri MT, Vasil AI. et al. Role of peptide hydrophobicity in the mechanism of action of α -helical antimicrobial peptides. *Antimicrob Agents Chemother*. 2007; 51(4): 1398–1406.
64. Conlon JM, Sonnevend Á, Patel M. et al. A family of brevinin-2 peptides with potent activity against *Pseudomonas aeruginosa* from the skin of the Hokkaido frog, *Rana pirica*. *Regul Pept*. 2004; 118(3): 135–141.
65. Phuong PT, Oliver S, He J. et al. Effect of hydrophobic groups on antimicrobial and hemolytic activity: Developing a predictive tool for ternary antimicrobial polymers. *Biomacromolecules*. 2020; 21(12): 5241–5255.
66. Conlon JM, Raza H, Coquet L. et al. Purification of peptides with differential cytolytic activities from the skin secretions of the Central American frog, *Lithobates vaillanti* (Ranidae). *Comp Biochem Physiol C Toxicol Pharmacol*. 2009; 150(2): 150–154.
67. Kumari VK, Nagaraj R. Structure– function studies on the amphibian peptide brevinin 1E: translocating the cationic segment from the C-terminal end to a central position favors selective antibacterial activity. *J Pept Res*. 2001; 58(5): 433–441.
68. Chen Q, Cheng P, Ma C. et al. Evaluating the bioactivity of a novel broad-spectrum antimicrobial peptide Brevinin-1GHa from the frog skin secretion of *Hylarana guentheri* and its analogues. *Toxins (Basel)*. 2018; 10(10): 413.
69. Zhou X, Liu Y, Gao Y. et al. Enhanced antimicrobial activity of N-terminal derivatives of a novel brevinin-1 peptide from the skin secretion of *Odorrana schmackeri*. *Toxins (Basel)*. 2020; 12(8): 484.
70. Chen G, Miao Y, Ma C. et al. Brevinin-2GHk from *Sylvirana guentheri* and the design of truncated analogs exhibiting the enhancement of antimicrobial activity. *Antibiotics (Basel)*. 2020; 9(2): 85.
71. Conlon JM, Al-Ghaferi N, Abraham B. et al. Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents. *Methods*. 2007; 42(4): 349–357.
72. Ma Z, Wei D, Yan P. et al. Characterization of cell selectivity, physiological stability and endotoxin neutralization capabilities of α -helix-based peptide amphiphiles. *Biomaterials*. 2015; 52: 517–530.
73. Abraham P, George S, Kumar KS. Novel antibacterial peptides from the skin secretion of the Indian bicoloured frog *Clinotarsus curtipes*. *Biochimie*. 2014; 97: 144–151.

نظرة ثاقبة على العلاقة بين التركيب والنشاط لببتيد بريفينين المضاد للميكروبات

محمد كمرول حسن أرنب¹، معين حسن¹، محمد منيرول إسلام^{2*}

¹ قسم الصيدلة، جامعة جاغاناث، دكا، بنغلاديش.

² قسم الصيدلة، جامعة نواخالي للعلوم والتكنولوجيا، نواخالي، بنغلاديش.

ملخص

تم العثور على العديد من أنواع البرمائيات، وخاصة تلك من جنس رنا، لإنتاج الببتيدات المضادة للميكروبات الخطية، البرمائية، والكاتيونية (AMPs) تكتسب AMPs مزيداً من الاهتمام في الاستخدامات الصيدلانية نظراً لطريقة عملها الرئيسية، والتي تستلزم اختراق وتمزيق أغشية الخلايا المقصودة بمقاومة منخفضة نسبياً Brevinin. هي عائلة كبيرة من AMPs تمت دراستها على نطاق واسع خلال العقود القليلة الماضية. تحتوي العائلة بشكل أساسي على مجموعتين من الببتيدات، وهما Brevinin-1 و Brevinin-2. هذه الببتيدات كاتيونية وتؤسس هياكل ثانوية في بيئة الغشاء البيولوجي. ناقش آثار المعلمات الهيكلية (شحنة صافية، كارهة للماء، amphiphilicity، حلزونية، طول الببتيد، إلخ) لبريفينين على نشاطها المضاد للميكروبات. كقاعدة عامة، ستؤدي زيادة الشحنة الصافية إلى زيادة نشاط مضادات الميكروبات. ومع ذلك، فإن الشحنات الصافية المفرطة تزيد أيضاً من النشاط الانحلالي. تؤثر تركيبة الأحماض الأمينية بشكل كبير على الكراهية للماء والطائرة، والتي بدورها تؤثر على نشاط الببتيدات. المعلمات الهيكلية مترابطة أيضاً؛ تغيير معلمة واحدة سيؤثر على الآخرين. سيعطي التغيير الأمثل في هذه العوامل نظير Brevinin أعلى نشاط مضاد للميكروبات ولكن أقل نشاط انحلالي.

الكلمات الدالة: الببتيدات المضادة للميكروبات؛ بريفينين، لولبية، كره الماء، صافي الشحن النشاط الانحلالي.

* المؤلف المراسل: محمد منيرول إسلام

monirul.phrm@nstu.edu.bd

تاريخ استلام البحث 2023/6/26 وتاريخ قبوله للنشر 2023/9/10.